PW Medtech Group Limited provided earnings guidance for the year ended December 31, 2023. The Group is expected to record (i) a net profit in the range of RMB 192 million to RMB 215 million for the year ended December 31, 2023, representing an increase of 49% to 67% as compared to that of approximately RMB129 million for the year ended December 31, 2022, and (ii) a profit attributable to owners of the Company in the range of RMB 142 million to RMB 165 million for the year ended December 31, 2023, representing an increase of 33% to 55% as compared to that of approximately RMB 106 million for the year ended December 31, 2022. Such increase is primarily due to a significant increase in the profit contributed by the Group's blood purification business and the infusion set business.